NEWS & PUBLICATIONS
Company and research updates span both therapeutic directions. Selected peer-reviewed work with Byterna-affiliated authors documents enabling science in AI-guided RNA design and circular-mRNA cell engineering.
LATEST UPDATES
At BIOHK 2026 in Hong Kong, co-founder and CEO Andy Xian Zeng, Ph.D., presented Byterna’s integrated strategy spanning transient, non-integrating in vivo CAR-T and AI-guided personalized neoantigen cancer vaccines.
Read update
Byterna, Insilico Medicine and Dune Quantum announced a collaboration connecting generative AI, heterogeneous quantum computing and programmable circular mRNA development.
Read update
At the 2026 Asia-Pacific RNA Excellence Awards ceremony in Singapore, Byterna CEO Andy Xian Zeng received the 2025 RNA Excellence Award for the Greater China Region.
Read updateCOMPANY & RESEARCH
Financing, collaborations, presentations and research progress tied to execution—not activity for its own sake.
The financing supports BR101 development and continued investment in Byterna’s personalized cancer-vaccine and programmable mRNA capabilities.
Joint preclinical work with Fudan University was selected for poster presentation at the Chimeric Antigen Receptor & Bispecific Antibody Summit.
At RNA Therapeutics & Manufacturing Asia, Byterna discussed circular mRNA innovation and in vivo CAR-T development.
Byterna announced Angel and Angel+ financing involving SunNovo Pharma, FOF Capital, Efung Capital and other investors.
Byterna presented preclinical work on circular mRNA-based CAR-T pharmacology and its potential for in vivo immune-cell programming.
Byterna announced municipal R&D support for circular RNA sequence design and chemical-modification research.
PEER-REVIEWED SCIENCE
Selected peer-reviewed work with Byterna-affiliated authors spans AI-guided RNA design and circular-mRNA cell engineering—two research areas central to the company's development work.
J. Chem. Inf. Model. 2025, 65, 6568–6584
This computational-methods study introduces RIdiffusion and reports benchmark performance on 3D RNA inverse-folding datasets; it does not constitute preclinical or clinical validation of a Byterna therapeutic candidate.
Authors listing Byterna Therapeutics as an affiliation: Shuai Zhang, Mengyao Ma and Hui Zhao. Xian Zeng lists Fudan University in the paper and is now with Byterna.Read in ACS Publications
Signal Transduction and Targeted Therapy 10, 411 (2025)
This preclinical study used ex vivo-engineered primary human T cells and evaluated CAR expression, in vitro function and antitumor activity in mouse models. It did not evaluate CellectLNP-mediated in vivo delivery or report BR101 human clinical results.
Byterna-affiliated co-author: Hui Zhao.Read in NatureMEDIA & SCIENTIFIC ENQUIRIES